 BOTHELL, Wash., June 09, 2021 GLOBE NEWSWIRE -- Cocrystal Pharma, Inc. Nasdaq: COCP, Cocrystal or the Company, a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that managements participation in the Noble Capital Markets C-Suite Interview Series is now available online. During the 30-minute video int e rview hosted by Noble Capital Markets Senior Equity Research Analyst Robert LeBoyer, Cocrystal discussed its antiviral drug-discovery and development work and provided program updates. 